<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-746
Date of Submission: 2025-08-05

This report was submitted by a Patient from Jones Group Medical Center concerning patient ANON-PX-9696. The subject is a 60-year-old male with a significant medical history including migraines, seasonal allergies, hypertension, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Gabapentin administered via the Intravenous route at a dosage of 16mg, initiated on 2025-07-16 for Neuropathic pain and discontinued on 2025-07-26.

On approximately 2025-07-21, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Nausea, Headache. The Hepatotoxicity was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Nausea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Headache was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Activity else sense by cover me at.</data>
report_id: ADR-2025-746
report_date: '2025-08-05'
patient_details:
  patient_id: ANON-PX-9696
  gender: Male
  relevant_history:
  - migraines
  - seasonal allergies
  - hypertension
  - atrial fibrillation
  age_at_reaction: 60
suspected_drugs:
- drug_name: Gabapentin
  dosage: 16mg
  route_of_administration: Intravenous
  start_date: '2025-07-16'
  indication_for_use: Neuropathic pain
  end_date: '2025-07-26'
adverse_reactions:
- symptom_name: Hepatotoxicity
  onset_date: '2025-07-21'
  severity: Moderate
  outcome: Recovered
  intervention_required: false
- symptom_name: Nausea
  onset_date: '2025-07-21'
  severity: Mild
  outcome: Fatal
  intervention_required: false
- symptom_name: Headache
  onset_date: '2025-07-21'
  severity: Mild
  outcome: Recovered
  intervention_required: false
causality_assessment:
  assessment_conclusion: Highly Probable
  dechallenge_rechallenge: Positive rechallenge
  naranjo_score: 9
reporting_facility: Jones Group Medical Center
reporter_type: Patient
notes: Activity else sense by cover me at.
